The North Carolina Department of Health and Human Services Division of Public Health has updated the 2023 Xylazine Exposure Guidance and offers new insights with immediate implications for clinical practice and frontline public health.
Xylazine was first introduced into the NC drug supply nearly three years ago and has become highly prevalent in the illicit opioid supply. In a February 2023 report from UNC’s Street Drug Analysis Lab, GCMS testing of street-acquired drug samples from 30 NC counties confirmed the presence of xylazine in approximately 27% of those samples.
Access the Xylazine Update for North Carolina Clinicians here.